Pharmaceutically acceptable salts and compositions thereof
Inventors
Gray, Jason • DEL RIO GANCEDO, Susana • Davis, Dita • Pearson, David James • Rixson, Daniel
Assignees
Macfarlan Smith Ltd • Beckley Psytech Ltd • Sygnature Discovery Ltd
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11773063-B1
Publication Date
2023-10-03
Expiration Date
Abstract
Pharmaceutically acceptable salts of 5-methoxy-N,N-dimethyltryptamine are described, as well as compositions/formulations and uses thereof as a medicament.
Core Innovation
The disclosure relates to crystalline solid forms of 5-MeO-DMT, with emphasis on crystalline salt forms characterized by XRPD diffractograms and corresponding XRPD peak patterns, together with thermal characterization and moisture-related assessments. It specifically describes 5-MeO-DMT hydrobromide as a non-hygroscopic crystalline salt form, while other salts are reported to show slight or moderate hygroscopicity, including phosphate and tartrate salts.
The non-hygroscopic character is supported by crystalline salt characterization, including XRPD diffractograms, defined crystalline patterns, and alternative XRPD peak-position descriptions. The document also provides solid-state characterization for 5-MeO-DMT phosphate, tartrate, hydrochloride, benzoate, benzenesulfonate, tosylate, glycolate, ketoglutarate, malate, saccharinate, fumarate, oxalate, and adipate, including polymorphic forms and PHO Pattern 1.
Thermal and structural characterization is also described using TGA, DSC, NMR, and DVS, including moisture sorption behavior, post-moisture XRPD retention or change of crystalline form, residual solvent content, and preliminary polymorph assessments. The disclosure further outlines stability behavior against moisture and/or conversion for some salts, and describes pharmaceutical compositions and use of the salt as a medicament for therapeutic indications.
Claims Coverage
The claim set covers a non-hygroscopic crystalline 5-MeO-DMT hydrobromide, XRPD-defined non-hygroscopic salt variants, and pharmaceutical compositions comprising the specified salt. The inventive features are the non-hygroscopic crystalline salt identity, XRPD peak-based crystalline definition, and inclusion of the defined salt in a pharmaceutical composition, for a total of five inventive features.
Non-hygroscopic crystalline 5-MeO-DMT hydrobromide
A non-hygroscopic salt of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), wherein the non-hygroscopic salt is 5-MeO-DMT hydrobromide and the non-hygroscopic salt is in crystalline form.
XRPD-defined non-hygroscopic salt using specific 2θ peak positions
A non-hygroscopic salt characterized by XRPD diffractogram peak positions at defined 2θ values measured with an x-ray wavelength of 1.5406 Å.
Alternative XRPD peak set for the non-hygroscopic salt
A non-hygroscopic salt characterized by specific XRPD peak positions at given 2θ values when measured under a specified x-ray wavelength.
XRPD diffractogram defined by a specific peak trio
A non-hygroscopic salt defined by specific XRPD diffractogram peak positions at 18.6°±10.1°, 19.7°±10.1°, and 24.8°±10.1° measured with an x-ray wavelength of 1.5406 Å.
Pharmaceutical composition comprising the non-hygroscopic salt
A pharmaceutical composition includes the non-hygroscopic salt from the dependent claims.
Overall, the claims cover a crystalline non-hygroscopic 5-MeO-DMT hydrobromide salt defined at the crystalline level, including XRPD-based peak definitions measured with an x-ray wavelength, and pharmaceutical compositions that include the specified non-hygroscopic salt variants.
Stated Advantages
The non-hygroscopic salt behavior supports improved handling of solid forms, with 5-MeO-DMT hydrobromide described as non-hygroscopic.
5-MeO-DMT hydrobromide is described as highly soluble, enabling simpler solid formulations in the disclosure.
Some salts are described as stable against moisture and/or conversion, as part of the characterization.
Supports solid-state identification via XRPD crystalline-form definitions and XRPD-based assessment after moisture-related exposure.
Provides characterization of moisture uptake behavior and retention or loss of crystalline form after DVS post-moisture exposure.
Documented Applications
Use of the salt as a medicament, including pharmaceutical compositions and dosage forms.
Therapeutic indications described include CNS dysfunctions, depression, anxiety, and substance-use/addiction disorders.
Pharmaceutical compositions comprising the specified non-hygroscopic salt variants.
Use of solid-state characterization (XRPD, TGA/DSC, and DVS) to define and assess crystalline salt forms and their moisture-related behavior under high relative humidity conditions.
Interested in licensing this patent?